Early pediatric anthracycline cardiotoxicity: managed by serial heart and bone marrow transplantation

J Heart Lung Transplant. 2007 Jun;26(6):658-60. doi: 10.1016/j.healun.2007.03.014.

Abstract

We report a favorable outcome in a child who underwent cardiac transplantation for severe early post-anthracycline-induced cardiomyopathy, 9 months after completion of treatment for acute myeloid leukemia (AML). The child suffered a relapse of AML 2 months after cardiac transplantation and then underwent a successful bone marrow transplant. This case is unique in the literature. We believe it offers an alternative strategy for children with hematologic malignancies, where severe early post-anthracycline cardiotoxicity might preclude bone marrow transplantation.

Publication types

  • Case Reports

MeSH terms

  • Anthracyclines / toxicity*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bone Marrow Transplantation*
  • Child
  • Heart Transplantation*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Pancytopenia / etiology
  • Recurrence
  • Survivors

Substances

  • Anthracyclines